Literature DB >> 29577372

Effect of tadalafil on chronic pelvic pain and prostatic inflammation in a rat model of experimental autoimmune prostatitis.

Ken Okamoto1, Maki Kurita1, Hiroshi Yamaguchi1, Yuki Numakura1, Michiko Oka1.   

Abstract

BACKGROUND: Experimental autoimmune prostatitis (EAP) shares important clinical features with clinical chronic prostatitis/chronic pelvic pain. We investigated the effect of tadalafil on pelvic pain and prostatic inflammation in a rat EAP model.
METHODS: EAP was induced in rats by intradermal injection of rat prostate antigen and complete Freund's adjuvant on days 0 and 28. Rats were treated with tadalafil (2 mg/kg, p.o.; EAP-tadalafil) or vehicle (EAP-vehicle) once daily from day 0, while sham-operated animals were treated with vehicle only (Sham). Tactile allodynia was measured on days 28, 35, and 42 by applying von Frey filaments to the lower abdomen as an index of pelvic pain. On day 42, the plasma immunoglobulin G (IgG) concentration and the testosterone/estradiol ratio were measured and histopathological analysis of the prostate was performed.
RESULTS: Tactile allodynia in the pelvic region was observed on days 28, 35, and 42 after EAP induction. The tactile allodynia observed on day 42 was significantly reduced by repeated treatment with tadalafil. Plasma IgG concentrations increased after EAP induction but the increase was not changed by tadalafil treatment. Prostate tissues were characterized by epithelial necrosis, infiltration of neutrophils and/or lymphocytes to acini and stroma, and fibrosis, in addition to a high stroma-to-epithelium ratio. Tadalafil treatment significantly suppressed the severity of the lesions.
CONCLUSIONS: EAP rats developed pelvic pain, prostatic inflammation and increased plasma IgG concentrations. Tadalafil inhibited the chronic pelvic pain and prostatic inflammation, suggesting that its anti-inflammatory action may contribute to its blocking of pain development in the EAP model.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  pelvic pain; prostatic inflammation; rat experimental autoimmune prostatitis; tadalafil

Mesh:

Substances:

Year:  2018        PMID: 29577372     DOI: 10.1002/pros.23514

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  HA/CD44 Regulates the T Helper 1 Cells Differentiation by Activating Annexin A1/Akt/mTOR Signaling to Drive the Pathogenesis of EAP.

Authors:  Jing Chen; Jialin Meng; Xiaoling Li; Xiao Li; Yi Liu; Chen Jin; Li Zhang; Zongyao Hao; Xianguo Chen; Meng Zhang; Chaozhao Liang
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

Review 2.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

3.  Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Andrea Benelli; Simone Mariani; Virginia Varca; Andrea Gregori; Franco Barrese; Manilo Cappa
Journal:  Ther Adv Urol       Date:  2018-10-26

4.  A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.

Authors:  Mikio Sugimoto; Xia Zhang; Nobufumi Ueda; Hiroyuki Tsunemori; Rikiya Taoka; Yusi Hayashida; Hiromi Hirama; Yasuyuki Miyauchi; Yuki Matsuoka; Hirohito Naito; Yu Osaki; Yosiyuki Kekehi
Journal:  BMC Urol       Date:  2019-10-23       Impact factor: 2.264

5.  Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome.

Authors:  Kevin Pineault; Shagnik Ray; Andrew Gabrielson; Amin S Herati
Journal:  Transl Androl Urol       Date:  2020-04

6.  Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way.

Authors:  Mengyang Zhang; Dongxu Lin; Changcheng Luo; Pengyu Wei; Kai Cui; Zhong Chen
Journal:  Oxid Med Cell Longev       Date:  2022-02-01       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.